No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BLCO240816C17500
- 0.50
- -0.13-20.63%
15min DelayClose Jul 19 15:58 ET
0.50High0.50Low
0.50Open0.63Pre Close8 Volume115 Open Interest17.50Strike Price400.00Turnover38.48%IV6.01%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type0.4183Delta0.2241Gamma33.96Leverage Ratio-0.0142Theta0.0047Rho14.20Eff Leverage0.0177Vega
Intraday
- 5D
- Daily
News
Express News | Bausch + Lomb : RBC Raises Target Price to $20 From $18
Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch
Express News | Bausch + Lomb : Raymond James Initiates Coverage With Outperform Rating; Price Target $19
Raymond James Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $19
Raymond James analyst Gary Nachman initiates coverage on $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and sets the target price at $19.According to TipRanks data, the analyst has a success rate
RBC Capital on Bausch + Lomb's Miebo, Xiidra, Prescription Numbers
RBC Capital notes that total prescriptions (TRx) for Bausch + Lomb's prescription for dry eye disease (DED), Miebo, increased week over week, while Xiidra (also for dry eye) printed a year over year d
Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief
New Online Resource, KnowYourDryEye.com, Aims to Increase Awareness and Education Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today
Comments
In today’s market, one of the biggest winners generating outsized interest is $Emergent BioSolutions(EBS.US$ . This mid-cap biotech company remains a unique turnaround story for investors, and many appear to be placing their bets on this company to come out of the pile as a key winner. Indeed, EBS stock has surged over 70% higher on some intriguing news this afternoon.
The company’s turnaround efforts appear to be receiving a jolt today, wit...
The company’s turnaround efforts appear to be receiving a jolt today, wit...
8
1
1
Upgrades
• $Argo Group International(ARGO.US$ : Compass Point Upgrades to Buy from Neutral - PT $28.50
• $Apache(APA.US$ : Citigroup Upgrades to Buy from Neutral - PT $58 (from $40)
• $Canadian National Railway(CNI.US$ : BofA Securities Upgrades to Buy from Neutral - PT $135 (from $128)
• $Canadian Pacific Railway(CP.US$ : BofA Securities Upgrades to Buy from Neutral - PT $87 (from $85)
• $Carpenter Technology(CRS.US$ : Cowen Upgra...
• $Argo Group International(ARGO.US$ : Compass Point Upgrades to Buy from Neutral - PT $28.50
• $Apache(APA.US$ : Citigroup Upgrades to Buy from Neutral - PT $58 (from $40)
• $Canadian National Railway(CNI.US$ : BofA Securities Upgrades to Buy from Neutral - PT $135 (from $128)
• $Canadian Pacific Railway(CP.US$ : BofA Securities Upgrades to Buy from Neutral - PT $87 (from $85)
• $Carpenter Technology(CRS.US$ : Cowen Upgra...
7
1
Upgrades
• $Argo Group International(ARGO.US$ : Compass Point Upgrades to Buy from Neutral - PT $28.50
• $Apache(APA.US$ : Citigroup Upgrades to Buy from Neutral - PT $58 (from $40)
• $Canadian National Railway(CNI.US$ : BofA Securities Upgrades to Buy from Neutral - PT $135 (from $128)
• $Canadian Pacific Railway(CP.US$ : BofA Securities Upgrades to Buy from Neutral - PT $87 (from $85)
• $Carpenter Technology(CRS.US$ : Cowen Upgr...
• $Argo Group International(ARGO.US$ : Compass Point Upgrades to Buy from Neutral - PT $28.50
• $Apache(APA.US$ : Citigroup Upgrades to Buy from Neutral - PT $58 (from $40)
• $Canadian National Railway(CNI.US$ : BofA Securities Upgrades to Buy from Neutral - PT $135 (from $128)
• $Canadian Pacific Railway(CP.US$ : BofA Securities Upgrades to Buy from Neutral - PT $87 (from $85)
• $Carpenter Technology(CRS.US$ : Cowen Upgr...
12
2
Upgrades
• $Zymergen(ZY.US$ : JPMorgan Upgrades to Neutral from Underweight
Downgrades
• $Chewy(CHWY.US$: Wedbush Downgrades to Neutral from Outperform - PT $44 (from $35)
• $Paramount Global-B(PARA.US$: Goldman Sachs Downgrades to Sell from Buy - PT $20 (from $37)
• $Roku Inc(ROKU.US$: Wolfe Research Downgrades to Underperform from Peerperform - PT $77
• $UBS Group(UBS.US$: BofA Securities Downgrades to Neutral from Buy - P...
• $Zymergen(ZY.US$ : JPMorgan Upgrades to Neutral from Underweight
Downgrades
• $Chewy(CHWY.US$: Wedbush Downgrades to Neutral from Outperform - PT $44 (from $35)
• $Paramount Global-B(PARA.US$: Goldman Sachs Downgrades to Sell from Buy - PT $20 (from $37)
• $Roku Inc(ROKU.US$: Wolfe Research Downgrades to Underperform from Peerperform - PT $77
• $UBS Group(UBS.US$: BofA Securities Downgrades to Neutral from Buy - P...
16
1
Read more
Benjamin’s : New CEO